ArticleCell death and differentiation2024
AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death.
Open access · greenAbstract read
In one paragraph
Article in Cell death and differentiation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Mitophagy and Cellular Homeostasis in Kidney Diseases: Mechanisms and Potential Therapeutics.International journal of biological sciences · 2026Review
- Chidamide enhances the sensitivity of gastric cancer to 5-fluorouracil chemotherapy by suppressing the HDAC3/HNF4A/TYMS axis.Cell death & disease · 2025Article
- Elimination of docetaxel-induced senescence attenuates malignant progression in RB1-deficient CRPC.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Downregulation of NAD Kinase Expression in β-Cells Contributes to the Aging-Associated Decline in Glucose-Stimulated Insulin Secretion.Aging cell · 2025Article
- Metabolomics analyses reveal the crucial role of ERK in regulating metabolic pathways associated with the proliferation of human cutaneous T-cell lymphoma cells treated with Glabridin.Cell proliferation · 2024Article
- Dorsomorphin attenuates ABCG2-mediated multidrug resistance in colorectal cancer.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 5 institutions in 3 countries.
Jia Jia *Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
Wenbo Ji *Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
Antoine N SalibaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Clifford M CsizmarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Kaiqin YeAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
Lei HuAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
Kevin L PetersonDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Paula A SchneiderDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
X Wei MengDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA.
Annapoorna VenkatachalamDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA.
Mrinal M PatnaikDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.ORCID 0000-0001-6998-662X
Jonathan A WebsterAdult Leukemia Program, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, 21287, USA.
B Douglas SmithAdult Leukemia Program, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, 21287, USA.
Gabriel GhiaurAdult Leukemia Program, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, 21287, USA.
Xinyan WuDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA.
Jun ZhongDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.ORCID 0000-0003-3148-4143
Akhilesh PandeyDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA.ORCID 0000-0001-9943-6127
Karen S FlattenDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Qingmei DengAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
Hongzhi WangAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
Scott H KaufmannDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA. Kaufmann.Scott@Mayo.edu.ORCID 0000-0002-4900-7145
Haiming DaiAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China. daih@cmpt.ac.cn.ORCID 0000-0002-0484-7407
Mayo Clinic · USMayo Clinic in Arizona · USChinese Academy of Sciences · CNSidney Kimmel Cancer Center · USUniversity of Science and Technology of China · CN
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MBAK Autoactivation in Hematological MalignanciesR01CA225996 · NCI · MAYO CLINIC ROCHESTER · PI KAUFMANN, SCOTT H · 2020 to 2024
$1.8MNCI NIH HHS P30 CA006973NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA225996
Abstract
BH3 mimetics, including the BCL2/BCLX
Indexed as
AMP-Activated Protein KinasesAniline Compoundsbcl-X ProteinMyeloid Cell Leukemia Sequence 1 ProteinPyrimidinesSulfonamidesAnimalsApoptosisbcl-Associated Death ProteinCell DeathCell Line, TumorDrug SynergismHumansLeukemiaMicePeptide FragmentsAMP-Activated Protein KinasesAniline CompoundsBAD protein, humanBCL2L1 protein, humanbcl-Associated Death Proteinbcl-X ProteindorsomorphinMCL1 protein, humanMyeloid Cell Leukemia Sequence 1 ProteinnavitoclaxPeptide FragmentsProto-Oncogene ProteinsPyrazolesPyrimidinesSulfonamides
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.